enVVeno Medical Corporation (NVNO)
| Previous Close | 4.9200 |
| Open | 5.0000 |
| Bid | 0.0000 x 0 |
| Ask | 5.0100 x 100 |
| Day's Range | 4.9332 - 5.1240 |
| 52 Week Range | 2.5100 - 6.9700 |
| Volume | |
| Avg. Volume | 123,990 |
| Market Cap | 66.65M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9100 |
| Earnings Date | Aug 05, 2024 - Aug 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREenVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Ended the quarter with $42.9 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025- Positive 11-month topline efficacy data presented at the 46th Annual Charing ...
ACCESSWIREPositive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including: 9.29 Points for Patients at the Two-Year Milestone 8.08 Points for ...
ACCESSWIRENew Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that additional topline efficacy data from ...
